Berger Financial Group Inc Has $4.64 Million Holdings in AbbVie Inc. $ABBV

Berger Financial Group Inc increased its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 41.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,025 shares of the company's stock after acquiring an additional 5,838 shares during the period. Berger Financial Group Inc's holdings in AbbVie were worth $4,637,000 as of its most recent SEC filing.3 Dividend Growth Stocks Analysts Are Upgrading for 2026Other hedge funds and other institutional investors have also bought and sold shares of the company. Hobart Private Capital LLC raised its holdings in shares of AbbVie by 4.4% in the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company's stock valued at $261,000 after purchasing an additional 48 shares during the last quarter. Rise Advisors LLC grew its position in AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company's stock valued at $336,000 after purchasing an additional 48 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of AbbVie by 1.1% in the second quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company's stock valued at $848,000 after acquiring an additional 51 shares during the last quarter. FF Advisors LLC grew its stake in AbbVie by 3.6% in the second quarter. FF Advisors LLC now owns 1,539 shares of the company's stock valued at $286,000 after purchasing an additional 53 shares in the last quarter. Finally, Landaas & Co. WI ADV grew its stake in AbbVie by 1.1% in the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company's stock valued at $920,000 after purchasing an additional 53 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock. AbbVie Stock PerformanceABBV opened at $227.82 on Tuesday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $402.64 billion, a P/E ratio of 172.59, a price-to-earnings-growth ratio of 1.29 and a beta of 0.36. The business's fifty day moving average is $226.58 and its 200-day moving average is $211.60. Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long HaulAbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year. AbbVie Increases DividendThe firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie's dividend payout ratio is currently 496.97%. Wall Street Analysts Forecast GrowthHIMS Has Been a Roller Coaster Ride. Should Investors Hop On?A number of brokerages have commented on ABBV. Weiss Ratings reiterated a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, October 8th. Wells Fargo & Company lifted their price objective on shares of AbbVie from $240.00 to $260.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. HSBC upgraded AbbVie from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Hsbc Global Res upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus price target of $245.84.Read Our Latest Analysis on ABBVAbout AbbVie (Free Report)AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas. AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.See AlsoFive stocks we like better than AbbVieDo not delete, read immediatelyINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffCan Any Expenses Be Deducted From Capital Gains Tax?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThe Last Gold Bull Market Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in AbbVie Right Now?Before you consider AbbVie, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here